CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with hematological malignancies; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.